González Sánchez E, López-Ríos Velasco J, Calvo Boizas E, García-Talavera Fernández J R, Martín Ro-dríguez M, Muñoz Herrera A, Del Cañizo Alvarez A
Dpto. de ORL, Hospital Universitario de Salamanca, Salamanca, Salamanca, 37005, España.
Acta Otorrinolaringol Esp. 1999 Mar;50(2):85-9.
Serum concentrations of Cyfra 21-1, a soluble cytokeratin fragment, were evaluated in 157 healthy patients, 66 patients with benign ear, nose or throat disease, and 102 patients with untreated epidermoid carcinoma of the head and neck. The technique had a sensitivity of 53.9% and specificity of 98.4% for a cutoff value of 1.5 ng/ml. Cyfra 21-1 levels differed significantly with tumor location (p < 0. 005) and tumor stage (p < 0.005), but not with the degree of histological differentiation.
对157名健康患者、66名患有耳鼻喉良性疾病的患者以及102名未经治疗的头颈部表皮样癌患者，评估了可溶性细胞角蛋白片段Cyfra 21-1的血清浓度。对于1.5 ng/ml的临界值，该技术的灵敏度为53.9%，特异性为98.4%。Cyfra 21-1水平因肿瘤位置（p < 0.005）和肿瘤分期（p < 0.005）而有显著差异，但与组织学分化程度无关。
